[Do thrombolytic agents have a place in the treatment of pulmonary embolism after the acute phase?].
D000792:Angiography; D012103:Batroxobin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D010446:Peptide Fragments / Q000032:analysis / Q000378:metabolism; D010958:Plasminogen / Q000032:analysis / Q000378:metabolism / Q000502:physiology; D011655:Pulmonary Embolism / Q000188:drug therapy*; D013300:Streptokinase / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D010446:Peptide Fragments; C018998:lysyl-plasminogen; D010958:Plasminogen; D006493:Heparin; D013300:Streptokinase; D012103:Batroxobin; D014568:Urokinase-Type Plasminogen Activator
Les thrombolytiques ont-ils leur place dans le traitement des embolies pulmonaires après la phase aiguë?